NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Sinovac Biotech Ltd. SVA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$386.0M
▲ 6.8% vs FY2024
EPS · FY25
$-0.83
Dividend / sh · FY25
$55.00
Payout · FY25
-1778%
ROE · FY25
-3.1%
Net margin · FY25
-51.5%
Dividend coverage
-0.0×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 386.0M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 52 cents on every revenue dollar this year.
Per share
USD -0.83
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-3.1%
Return on equity, FY2025
ROE
Operating margin-127.0%
Net margin-51.5%
Return on assets-1.9%
Each USD of equity lost 3 cents this year.
Returned to shareholders
USD 3.5B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 3.5B
Net buybacks—
Share of profit-1777.5%
Consecutive raises—
USD 3.5B in dividends went back to shareholders in a year without profit.
Growth
−5.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−36.0%
−5.4%
+19.1%
+17.7%
Returned to shareholders
+142.6%
+59.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years−27.6%
Change, 10 years+26.3%
The share count shrank 28% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.5B
total assets, end of FY2025
Total assetsUSD 8.5B
EquityUSD 4.4B
CashUSD 488.2M
Gross debtUSD 494.9M
Net debtUSD 6.6M
Current ratio4.59×
Net debt stands at 0% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.4
0.4
0.5
1.5
19.4
0.5
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.0
0.1
0.0
0.1
Operating income $B
−0.5
−0.5
−0.7
−0.5
17.6
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
EBITDA $B
−0.4
−0.4
−0.6
−0.4
17.7
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
Income tax $B
−0.1
0.0
0.0
0.0
3.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
Net income $B
−0.2
0.0
−0.1
0.0
8.1
0.1
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−0.83
1.27
−0.19
0.20
113.44
0.97
0.41
0.34
0.45
−0.01
−0.03
−0.03
0.13
−0.27
−0.02
−0.16
0.46
Dividend / sh $
55.00
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−1778
2329
−271
1710
23
0
0
·
·
·
·
·
·
−4
−1469
−26
19
ROE %
−3.1
0.5
−1.4
0.2
166.8
21.2
16.4
10.8
19.3
−0.5
−1.1
−1.2
6.0
−15.1
−0.3
−10.0
·
Shares out B
0.07
0.07
0.07
0.07
0.07
0.10
0.10
0.07
0.06
0.06
0.06
0.06
0.06
0.06
0.05
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed